ArticleCureus2026
Pelvic Exenteration for Advanced and Recurrent Gynecologic Malignancies: Surgical Morbidity and Survival Outcomes From a Tertiary Cancer Center.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Pelvic exenteration (PE) involves en-bloc removal of central pelvic organs and is indicated for patients with locally advanced or recurrent cervical, endometrial, ovarian, vaginal, and vulvar cancers. Our study aimed to analyze the surgical morbidity and survival in patients who underwent pelvic exenteration surgery for gynecological malignancies. Methods Sixty patients underwent pelvic exenteration for gynecological malignancy at our centre from January 2013 to December 2020. We included all patients who underwent a pelvic exenteration procedure for locally advanced or recurrent cervical, ovarian, endometrial, vaginal and vulvar cancers with both curative and palliative intent. The primary objective was to analyze the perioperative complications, pattern and severity of perioperative morbidity, and the requirement for reconstruction procedures. The secondary objective was to analyze the disease-free survival (DFS) and overall survival (OS) associated with this radical procedure Results Among 60 patients who underwent the exenteration procedure, total, anterior, and posterior exenteration was performed in two (3.33%), two (3.33%), and 56 (93.33%) patients, respectively. Intraoperative complications occurred in 13 cases. Median follow-up period was 50 months. The OS rates were 87.7% at one year, 78.5% at two years, 58% at three years, and 36.6% at four years and DFS showed a similar declining trend over time, with 75.1% of patients remaining disease-free at one year, 50.0% at two years, 28.0% at three years, and 25.7% at four years. Conclusion In summary, pelvic exenteration is a definite option in indicated cases of advanced gynecological malignancies in the background of advanced surgical techniques, modern intensive care facilities, and surgical expertise. With respect to survival benefits, exenteration procedures are associated with an acceptable rate of major complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.